Cargando…
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
BACKGROUND: In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on the clini...
Autores principales: | Blomstrand, Hakon, Scheibling, Ursula, Bratthäll, Charlotte, Green, Henrik, Elander, Nils O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325739/ https://www.ncbi.nlm.nih.gov/pubmed/30621618 http://dx.doi.org/10.1186/s12885-018-5244-2 |
Ejemplares similares
-
Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
por: Blomstrand, Hakon, et al.
Publicado: (2020) -
Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021) -
Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021) -
Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020) -
Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)